CEDAR KNOLLS, NJ--(Marketwired - Sep 4, 2014) - MYOS Corporation ("MYOS" or the "Company") (
A live audio webcast of the presentation will be available on the Company's website ( www.myoscorp.com ) in the Investor Relations section ( http://ir.myoscorp.com/ ) on the Upcoming Events page on the IR Calendar at http://ir.myoscorp.com/ir-calendar . The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.
About MYOS Corporation MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin ™ , the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company ™ ," visit www.myoscorp.com .
The Company's first commercial product containing Fortetropin ( MYO-T12 ), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X ® and is currently available on popular retailer websites including http://mhpstrong.com , www.bodybuilding.com , www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
MYOS Corporation Investor and Media Contact: Jenene Thomas Investor Relations and Corporate Communications (973) 509-0444 Email Contact
